Utility Menu

Powder/Bulk Solids

The Source for Dry Processing and Bulk Handling Technology

Pfizer Mulls Sale of $14B Consumer Healthcare Unit

October 10, 2017
Pfizer is considering options for the future of its Consumer Healthcare business, which includes brands like Advil. Image courtesy of Flickr user armydre2008
Pfizer is considering options for the future of its Consumer Healthcare business, which includes brands like Advil. Image courtesy of Flickr user armydre2008

Biopharmaceutical firm Pfizer is considering a number of “strategic alternatives” including a spin-off or sale, for its $100 million Consumer Healthcare business, the German firm announced via press release Tuesday. While Pfizer said it may ultimately retain the business, its future with the company appears uncertain.

Including well-known brands like Advil, Robitussin, Centrum, and ChapStick, Pfizer’s Consumer Healthcare business produces a number of over-the-counter (OTC) medicines, personal care products, and vitamins.

“Although there is a strong connection between Consumer Healthcare and elements of our core biopharmaceutical businesses, it is also distinct enough from our core business that there is potential for its value to be more fully realized outside the company,” the firm’s chairman and chief executive officer, Ian Read, said in a statement. “By exploring strategic options, we can evaluate how best to fuel the future success and expansion of Consumer Healthcare while simultaneously unlocking potential value for our shareholders.”

Some industry observers told Reuters that the sale price of Pfizer’s business could reach four times its annual sales of $3.4 billion in 2016, or about $14 billion. Pfizer said it will make a decision on the matter in 2018 following a strategic review process.

For more news headlines, articles, and equipment reviews, visit our Equipment Zones